Neurocognitive profiles structure heterogeneous treatment response to bumetanide in neurodevelopmental disorders: secondary analysis of a multiple baseline single-case experimental design

We performed a secondary analysis of the Bumetanide for Developmental Disorders (BUDDI;EUDRA-CT-2020-002196-35) trial to examine whether baseline neurocognitive profiles are associated with differential behavioral and cognitive treatment response. Participants (7-19 years) with atypical sensory reactivity and ASD, ADHD, epilepsy, or TSC diagnoses received 6-months of bumetanide treatment (max 3.0 mg/day) within a multiple-baseline SCED. Neurocognitive functioning was assessed across multiple…

via https://pubmed.ncbi.nlm.nih.gov/43037653/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20261117021015&v=2.20.1


Post a Comment

Your email is never published nor shared. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>